--- title: "Heart Failure CONFIRMATION-HF | Sutter Health" description: "Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)" url: "https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Heart Failure CONFIRMATION-HF # Heart Failure CONFIRMATION-HF **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06024746?term=202303CPC&rank=1). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure. This is an international, randomized, controlled, open-label, trial of an early, intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor (SGLT2i) compared with usual care in patients hospitalized with heart failure (HF) ![Gurpreet S Sodhi, M.D.](https://dyn.mktgcdn.com/p/_DPw7axqv4PbIJjFjLDp5slcyPsexcunwo7V0wWSlII/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Gurpreet S Sodhi, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/gurpreet-s-sodhi-md-1049681244) ## Sub-Investigators [Zijian Xu, M.D., Ph.D., FACC](https://www.sutterhealth.org/research/investigators/zijian-xu-md-phd-facc-1049681028) , [Michael A Gibson, M.D.](https://www.sutterhealth.org/research/investigators/michael-a-gibson-md-1097247582) ## Email us to enroll - [Email Sacramento](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Heart%20Failure%20CONFIRMATION-HF%20in%20Sacramento&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Heart Failure - TEAM-HF](https://www.sutterhealth.org/research/clinical-trials/advancing-heart-failure-team-hf-1097247574) Trial to Evaluate Safety and Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure **Status:** Open to Enrollment - Clinical trial ### [Heart Failure COMET-HF](https://www.sutterhealth.org/research/clinical-trials/heart-failure-comet-hf-2015330118) A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF) **Status:** Open to Enrollment - Clinical trial ### [Heart Failure FINALITY-HF](https://www.sutterhealth.org/research/clinical-trials/heart-failure-finality-hf-2005599814) A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF) **Status:** Open to Enrollment - Clinical trial ### [Heart Failure REDEFINE-HF](https://www.sutterhealth.org/research/clinical-trials/heart-failure-redefine-hf-1095250384) Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF) **Status:** Open to Enrollment - Clinical trial ### [Heart Failure AIM HIGHer Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System CA\_CP\_340](https://www.sutterhealth.org/research/clinical-trials/heart-failure-aim-higher-cardiac-contractility-modulation-therapy-via-optimizer-smart-mini-system-ca_cp_340-2077445142) Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Heart Failure CONFIRMATION-HF"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414#medicalwebpage","name":"Heart Failure CONFIRMATION-HF","description":"Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)","url":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414","inLanguage":"en-US","dateModified":"2026-06-01","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414#breadcrumblist"},"mentions":[{"@type":"Person","name":"Gurpreet S Sodhi, M.D.","url":"https://www.sutterhealth.org/research/investigators/gurpreet-s-sodhi-md-1049681244","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414#medicaltrial","name":"Heart Failure CONFIRMATION-HF","alternateName":"Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)","url":"https://www.sutterhealth.org/research/clinical-trials/heart-failure-confirmation-hf-1095250414","description":"Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure. This is an international, randomized, controlled, open-label, trial of an early, intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor (SGLT2i) compared with usual care in patients hospitalized with heart failure (HF)","identifier":"NCT06024746","code":{"@type":"MedicalCode","codeValue":"NCT06024746","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT06024746?term=202303CPC&rank=1","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Heart Failure"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```